Literature DB >> 28223395

Oxygen therapy for interstitial lung disease: a systematic review.

Emily C Bell1, Narelle S Cox1,2,3, Nicole Goh3,4,5, Ian Glaspole5,6, Glen P Westall5,6, Alice Watson2, Anne E Holland7,3,8.   

Abstract

This review aims to establish the impact of oxygen therapy on dyspnoea, health-related quality of life (HRQoL), exercise capacity and mortality in interstitial lung disease (ILD).We included studies that compared oxygen therapy to no oxygen therapy in adults with ILD. No limitations were placed on study design or intervention type. Two reviewers independently evaluated studies for inclusion, assessed risk of bias and extracted data. The primary outcome was dyspnoea.Eight studies evaluated the acute effects of oxygen (n=1509). There was no effect of oxygen therapy on modified Borg dyspnoea score at end exercise (mean difference (MD) -0.06 units, 95% CI -0.24-0.13; two studies, n=27). However, effects on exercise outcomes consistently favoured oxygen therapy. One study showed reduction in dyspnoea at rest with oxygen in patients who were acutely unwell (MD visual analogue scale 30 mm versus 48 mm, p<0.05; n=10). Four studies of long-term oxygen therapy (n=2670) had high risk of bias and no inferences could be drawn.This systematic review showed no effects of oxygen therapy on dyspnoea during exercise in ILD, although exercise capacity was increased. Future trials should evaluate whether acute improvements in exercise capacity with oxygen can be translated into improved physical activity and HRQoL.
Copyright ©ERS 2017.

Entities:  

Mesh:

Year:  2017        PMID: 28223395     DOI: 10.1183/16000617.0080-2016

Source DB:  PubMed          Journal:  Eur Respir Rev        ISSN: 0905-9180


  22 in total

Review 1.  Idiopathic Pulmonary Fibrosis: Best Practice in Monitoring and Managing a Relentless Fibrotic Disease.

Authors:  Wim A Wuyts; Marlies Wijsenbeek; Benjamin Bondue; Demosthenes Bouros; Paul Bresser; Carlos Robalo Cordeiro; Ole Hilberg; Jesper Magnusson; Effrosyni D Manali; António Morais; Spyridon Papiris; Saher Shaker; Marcel Veltkamp; Elisabeth Bendstrup
Journal:  Respiration       Date:  2019-12-12       Impact factor: 3.580

2.  Exercise Tolerance in Patients With Idiopathic Pulmonary Fibrosis, Effect of Supplemental Oxy-Gen.

Authors:  J Chlumský; L Stehlík; M Šterclová; J Smetanová; O Zindr
Journal:  Physiol Res       Date:  2022-04-11       Impact factor: 2.139

3.  Pulmonary hypertension in chronic lung disease and hypoxia.

Authors:  Steven D Nathan; Joan A Barbera; Sean P Gaine; Sergio Harari; Fernando J Martinez; Horst Olschewski; Karen M Olsson; Andrew J Peacock; Joanna Pepke-Zaba; Steeve Provencher; Norbert Weissmann; Werner Seeger
Journal:  Eur Respir J       Date:  2019-01-24       Impact factor: 16.671

4.  Resilience and health-related quality of life in patients with pulmonary diseases receiving ambulatory oxygen therapy.

Authors:  Siiri Isokääntä; Kirsi Honkalampi; Hannu Kokki; Harri Sintonen; Merja Kokki
Journal:  BMC Pulm Med       Date:  2021-05-01       Impact factor: 3.320

Review 5.  Clinical use of nintedanib in patients with idiopathic pulmonary fibrosis.

Authors:  Amy Hajari Case; Peace Johnson
Journal:  BMJ Open Respir Res       Date:  2017-06-28

Review 6.  The Management of Patients With Idiopathic Pulmonary Fibrosis.

Authors:  Paolo Spagnolo; Argyris Tzouvelekis; Francesco Bonella
Journal:  Front Med (Lausanne)       Date:  2018-07-02

Review 7.  Impact of novel antifibrotic therapy on patient outcomes in idiopathic pulmonary fibrosis: patient selection and perspectives.

Authors:  Bridget A Graney; Joyce S Lee
Journal:  Patient Relat Outcome Meas       Date:  2018-09-21

Review 8.  Comorbidities, Complications and Non-Pharmacologic Treatment in Idiopathic Pulmonary Fibrosis.

Authors:  Paloma Millan-Billi; Candela Serra; Ana Alonso Leon; Diego Castillo
Journal:  Med Sci (Basel)       Date:  2018-07-24

Review 9.  Ongoing clinical trials and treatment options for patients with systemic sclerosis-associated interstitial lung disease.

Authors:  Dinesh Khanna; Donald P Tashkin; Christopher P Denton; Martin W Lubell; Cristina Vazquez-Mateo; Stephen Wax
Journal:  Rheumatology (Oxford)       Date:  2019-04-01       Impact factor: 7.580

10.  Hyperbaric Oxygen Ameliorates Bleomycin-Induced Pulmonary Fibrosis in Mice.

Authors:  Yuan Yuan; Yali Li; Guoqiang Qiao; Yilu Zhou; Zijian Xu; Charlotte Hill; Zhenglin Jiang; Yihua Wang
Journal:  Front Mol Biosci       Date:  2021-06-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.